These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28155580)

  • 1. Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Manouchehrinia A; Westerlind H; Kingwell E; Zhu F; Carruthers R; Ramanujam R; Ban M; Glaser A; Sawcer S; Tremlett H; Hillert J
    Mult Scler; 2017 Dec; 23(14):1938-1946. PubMed ID: 28155580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Multiple Sclerosis Severity Score in a large US cohort.
    Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T;
    Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and diagnostic features of patients with familial multiple sclerosis.
    Andrijauskis D; Balnyte R; Keturkaite I; Vaitkus A
    Med Hypotheses; 2019 Oct; 131():109310. PubMed ID: 31443766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Zhou Y; Claflin SB; Stankovich J; van der Mei I; Simpson S; Roxburgh RH; Kalincik T; Blizzard L; Lugaresi A; Alroughani R; Sajedi SA; Butzkueven H; Pucci E; Spitaleri D; Granella F; Cristiano E; Yamout B; Hughes S; Gouider R; Sánchez Menoyo JL; Olascoaga J; McGuigan C; Shaw C; Kermode AG; Kasa K; Al-Harbi T; Altintas A; Laureys G; Fragoso Y; Hardy TA; Csepany T; Sirbu CA; Decoo D; Sas A; Alvarez-Cermeño JC; Kotkata K; Millán-Pascual J; Taylor BV
    Mult Scler; 2020 Nov; 26(13):1765-1774. PubMed ID: 31668127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between onset age and disability in multiple sclerosis patients studied using MSSS and a progression model.
    Ramachandran S; Strange RC; Jones PW; Kalra S; Nayak D; Hawkins CP
    Mult Scler Relat Disord; 2014 Sep; 3(5):593-9. PubMed ID: 26265271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multiple sclerosis severity score (MSSS) predicts disease severity over time.
    Pachner AR; Steiner I
    J Neurol Sci; 2009 Mar; 278(1-2):66-70. PubMed ID: 19138773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.
    Kister I; Chamot E; Bacon JH; Cutter G; Herbert J;
    Mult Scler; 2011 Jun; 17(6):725-33. PubMed ID: 21270059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and quality of life of multiple sclerosis in the United Kingdom.
    Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and disease disability in immigrants with multiple sclerosis in Malmö, southern Sweden.
    Alonso-Magdalena L; Carmona I Codina O; Zia E; Sundström P; Pessah-Rasmussen H
    Clin Neurol Neurosurg; 2024 May; 240():108255. PubMed ID: 38552363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum NSE level and disability progression in multiple sclerosis.
    Koch MW; George S; Wall W; Wee Yong V; Metz LM
    J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.
    Manouchehrinia A; Tench CR; Maxted J; Bibani RH; Britton J; Constantinescu CS
    Brain; 2013 Jul; 136(Pt 7):2298-304. PubMed ID: 23757766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and quality of life of multiple sclerosis in Sweden.
    Berg J; Lindgren P; Fredrikson S; Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
    Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
    Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Kalincik T; Kister I; Bacon TE; Malpas CB; Sharmin S; Horakova D; Kubala-Havrdova E; Patti F; Izquierdo G; Eichau S; Ozakbas S; Onofrj M; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Boz C; Grand'Maison F; Bergamaschi R; Gerlach O; Sa MJ; Kappos L; Cartechini E; Lechner-Scott J; van Pesch V; Shaygannejad V; Granella F; Spitaleri D; Iuliano G; Maimone D; Prevost J; Soysal A; Turkoglu R; Ampapa R; Butzkueven H; Cutter G;
    Mult Scler; 2022 Oct; 28(11):1752-1761. PubMed ID: 35373638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.